PMID- 22885888
OWN - NLM
STAT- MEDLINE
DCOM- 20130109
LR  - 20220129
IS  - 1473-6322 (Electronic)
IS  - 1528-4050 (Print)
IS  - 1473-6322 (Linking)
VI  - 12
IP  - 5
DP  - 2012 Oct
TI  - Safety of engineered allergen-specific immunotherapy vaccines.
PG  - 555-63
LID - 10.1097/ACI.0b013e328357ca53 [doi]
AB  - PURPOSE OF REVIEW: The purpose of the review is to summarize and comment on 
      recent developments regarding the safety of engineered immunotherapy vaccines. 
      RECENT FINDINGS: In the last 2 years, several studies were published in which 
      allergy vaccines were developed on the basis of chemical modification of natural 
      allergen extracts, the engineering of allergen molecules by recombinant DNA 
      technology and synthetic peptide chemistry, allergen genes, new application 
      routes and conjugation with immune modulatory molecules. Several studies 
      exemplified the general applicability of hypoallergenic vaccines on the basis of 
      recombinant fusion proteins consisting of nonallergenic allergen-derived peptides 
      fused to allergen-unrelated carrier molecules. These vaccines are engineered to 
      reduce both, immunoglobulin E (IgE) as well as allergen-specific T cell epitopes 
      in the vaccines, and thus should provoke less IgE and T-cell-mediated 
      side-effects. They are made to induce allergen-specific IgG antibodies against 
      the IgE-binding sites of allergens with the T-cell help of the carrier molecule. 
      SUMMARY: Several interesting examples of allergy vaccines with potentially 
      increased safety profiles have been published. The concept of fusion proteins 
      consisting of allergen-derived hypoallergenic peptides fused to 
      allergen-unrelated proteins that seems to be broadly applicable for a variety of 
      allergens appears to be of particular interest because it promises not only to 
      reduce side-effects but also to increase efficacy and convenience of allergy 
      vaccines.
FAU - Focke-Tejkl, Margarete
AU  - Focke-Tejkl M
AD  - Division of Immunopathology, Department of Pathophysiology and Allergy Research, 
      Medical University of Vienna, Vienna, Austria.
FAU - Valenta, Rudolf
AU  - Valenta R
LA  - eng
GR  - F 4605/FWF_/Austrian Science Fund FWF/Austria
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Allergy Clin Immunol
JT  - Current opinion in allergy and clinical immunology
JID - 100936359
RN  - 0 (Allergens)
RN  - 0 (Vaccines, DNA)
SB  - IM
MH  - Allergens/administration & dosage/*adverse effects/*genetics/immunology
MH  - Animals
MH  - Cats
MH  - Clinical Trials as Topic
MH  - Desensitization, Immunologic/*adverse effects/methods
MH  - Genetic Engineering/adverse effects/methods
MH  - Humans
MH  - Hypersensitivity, Immediate/*therapy
MH  - Treatment Outcome
MH  - Vaccines, DNA/administration & dosage/*adverse effects/genetics/immunology
PMC - PMC4594771
MID - EMS65104
OID - NLM: EMS65104
EDAT- 2012/08/14 06:00
MHDA- 2013/01/10 06:00
PMCR- 2015/10/06
CRDT- 2012/08/14 06:00
PHST- 2012/08/14 06:00 [entrez]
PHST- 2012/08/14 06:00 [pubmed]
PHST- 2013/01/10 06:00 [medline]
PHST- 2015/10/06 00:00 [pmc-release]
AID - 10.1097/ACI.0b013e328357ca53 [doi]
PST - ppublish
SO  - Curr Opin Allergy Clin Immunol. 2012 Oct;12(5):555-63. doi: 
      10.1097/ACI.0b013e328357ca53.